Disclosed is the use of a monoclonal or polyclonal antibody or an antigen binding fragment thereof comprising an antigen binding site that binds specifically to an extracellular domain of a polypeptide consisting essentially of 108, 145, or 170 amino acids of the amino acid sequence set forth in SEQ ID NO:62, or a pharmaceutical composition comprising same in a pharmaceutically acceptable diluent or carrier, in the manufacture of a medicament for treatment of cancer.
